Evidence map›Paper›PMID 35255395›Full record

ArticleJournal of colloid and interface science2022

Drug delivery of memantine with carbon dots for Alzheimer's disease: blood-brain barrier penetration and inhibition of tau aggregation.

Wei Zhang, Nabin Kandel, Yiqun Zhou, Nathan Smith, Braulio C L B Ferreira, Miranda Perez, Matteo L Claure, Keenan J Mintz, Chunyu Wang, Roger M Leblanc

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of colloid and interface science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Wei ZhangDepartment of Chemistry, University of Miami, Coral Gables, FL 33146, USA.
Nabin KandelDepartment of Biological Sciences, Rensselaer Polytechnic Institute, NY 12180, USA.
Yiqun ZhouC-Dots, LLC, Miami, FL 33136, USA.
Nathan SmithDepartment of Biological Sciences, Rensselaer Polytechnic Institute, NY 12180, USA.
Braulio C L B FerreiraDepartment of Chemistry, University of Miami, Coral Gables, FL 33146, USA.
Miranda PerezDepartment of Chemistry, University of Miami, Coral Gables, FL 33146, USA.
Matteo L ClaureDepartment of Chemistry, University of Miami, Coral Gables, FL 33146, USA.
Keenan J MintzDepartment of Chemistry, University of Miami, Coral Gables, FL 33146, USA.
Chunyu WangDepartment of Biological Sciences, Rensselaer Polytechnic Institute, NY 12180, USA.
Roger M LeblancDepartment of Chemistry, University of Miami, Coral Gables, FL 33146, USA. Electronic address: rml@miami.edu.
University of Miami · USRensselaer Polytechnic Institute · US

Funding

Heparan Sulfate 3-O-Sulfation in Transcellular Propagation of Tauopathy in Alzheimer's DiseaseRF1AG069039 · NIA · RENSSELAER POLYTECHNIC INSTITUTE · PI LINHARDT, ROBERT J, LIU, JIAN · 2020 to 2020
$2.6M
NIA NIH HHS RF1 AG069039
6 · The paper itself

Abstract

Neurofibrillary tangle, composed of aggregated tau protein, is a pathological hallmark of Alzheimer's disease (AD). The inhibition of tau aggregation is therefore an important direction for AD drug discovery. In this work, we explored the efficacy of two types of carbon dots in targeting tau aggregation, as versatile nano-carriers for the development of carbon dots (CDs)-based AD therapy. We carried out synthesis, biophysical and biochemical characterizations of two types of CDs, namely, carbon nitride dots (CNDs) and black carbon dots (B-CDs). CDs, which are biocompatible and non-toxic, were successfully conjugated with memantine hydrochloride (MH) through EDC/NHS mediated amidation reactions followed by systematic characterizations using various biophysical techniques including UV-vis spectroscopy (UV-vis), photoluminescence (PL), Fourier-transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), mass spectrometry (MS), Transmission electron microscopy (TEM) and atomic force microscopy (AFM). The surface diversity along with small particle sizes of CDs allowed facile delivery of MH across the blood-brain barrier (BBB), as demonstrated using a zebrafish in vivo model. The tau aggregation inhibition experiments were conducted using the thioflavin-T (ThT) assay to identify the most effective inhibitor. The kinetics and magnitude of tau aggregation were measured in the presence of CDs, which demonstrates that both B-CDs-MH and B-CDs alone are the most effective inhibitors of tau aggregation with IC

Indexed as

Alzheimer DiseaseQuantum DotsAnimalsBlood-Brain BarrierCarbonMemantinetau ProteinsZebrafishCarbonMemantinetau ProteinsAlzheimer’s diseaseBlood–brain barrierCarbon dotsMemantineTau protein aggregation

Identifiers

PMID35255395
PMCPMC9520758
OpenAlexW4214502944

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.